
Jan 9 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONES
RHYTHM PHARMACEUTICALS INC - MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY
RHYTHM PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EXPECTED Q1 2026
RHYTHM PHARMACEUTICALS INC - FY 2025 PRELIM PRODUCT REVENUES ABOUT $194 MILLION, UP 50% FROM FY2024
RHYTHM PHARMACEUTICALS INC - PRELIM Q4 2025 IMCIVREE REVENUES ABOUT $57 MILLION, UP 11% FROM Q3